glp-1 news today november 5 2025 Opinion | Experimentation Is Everywhere, and Science Can't Keep Up Frontiers | GLP-1 agonists and

Liu S, Wu W, Chen Q, Zheng Z, Jiang X, Xue Y, et al

IV infusions often provide an immediate boost in energy or immunity, lasting days to weeks

Sin embargo, a diferencia de los genricos qumicos que son idnticos al original, los biosimilares requieren estudios clnicos propios para demostrar que funcionan igual, lo que retrasa su llegada al mercado incluso despus del vencimiento de patentes

Remote and Rural Patient Populations With longer transit times and exposure to unpredictable ambient conditions, rural deliveries present greater challenges

and An outside, existential chance you win patent/IP disputes over Big Pharma to continue offering slightly different GLP-1s to consumers long-term (or some sort of other sustainable workaround)

Br J Pharm